Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02052

6-sulfo LacNAc (slan) as a marker for non-classical monocytes

 Thomas P. Hofer1, Arjan A. van de Loosdrecht2, Christiane Stahl-Hennig3,  Marco A. Cassatella4 and  Loems Ziegler-Heitbrock5*
  • 1Immunoanalytics Core Facility, Helmholtz Centre Munich, Germany
  • 2Department of Hematology, VU University Medical Center, Netherlands
  • 3Deutsches Primatenzentrum, Germany
  • 4Section of General Pathology, Department of Medicine, University of Verona, Italy
  • 5Independent researcher, Germany

Monocytes are subdivided into three subsets, which have different phenotypic and functional characteristics and different roles in inflammation and malignancy. When in man CD14 and CD16 monoclonal antibodies are used to define these subsets, then the distinction of non-classical CD14low and intermediate CD14high monocytes requires setting a gate in what is a gradually changing level of CD14 expression. In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan). Slan is a carbohydrate residue originally described to be expressed on the cell surface of a type of dendritic cell in human blood. We elaborate herein that the features of slan+ cells are congruent with the features of CD16+ non-classical monocytes and that slan is a candidate marker for definition of non-classical monocytes. The use of this marker may help in studying the role of non-classical monocytes in health and in diagnosis and monitoring of disease.

Keywords: monocyte subsets, SLAN, man, monkey, Inflammation, Cancer, CMML, Lymphoma

Received: 14 May 2019; Accepted: 14 Aug 2019.

Edited by:

Claudia Jakubzick, Department of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, United States

Reviewed by:

Frank Tacke, University Hospital RWTH Aachen, Germany
Peter Henson, National Jewish Health (United States), United States  

Copyright: © 2019 Hofer, van de Loosdrecht, Stahl-Hennig, Cassatella and Ziegler-Heitbrock. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Loems Ziegler-Heitbrock, Independent researcher, Munich, 82131, Germany, LZH@monocyte.eu